Virat Gupta

Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).

Cooley advised Infleqtion, a global leader in neutral atom-based quantum technology, on its definitive business combination agreement with Churchill Capital Corp X, with the aim to accelerate Infleqtion’s mission to commercialize quantum products that provide orders of magnitude improvement in computing and precision sensing applications.

Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly.

Cooley previously advised Impact Analytics, a leader in artificial intelligence (AI)-native innovation and the only provider of an end-to-end platform for pricing, merchandising and supply chain on the close of its Series D funding round led by Blue Cloud Ventures.

Cooley advised Cerberus Capital Management, a global leader in alternative investing with approximately $65 billion in assets across complementary credit, real estate and private equity strategies, on its growth investment in Aquatech, a global leader in water technology and services for industrial and infrastructure markets.